金纳多治疗急性缺血性脑卒中临床疗效观察

Clinical efficacy observation of Ginaton in the treatment of acute ischemic stroke

目的观察金纳多治疗急性缺血性脑卒中患者的临床疗效和安全性。方法选取我院2012年1月-2013年12月收治的急性缺血性脑卒中患者84例,随机分成观察组和对照组各42例,观察组在常规治疗的基础上给予金纳多注射液静滴,对照组在常规治疗的基础上给予血塞通注射液静滴,两组均连续应用14d。于治疗前及疗程结束后分别对两组患者进行神经功能缺损评分及血液流变血塞通注射液静滴学检查,同时记录不良反应发生情况,对比分析两组的临床效果和用药安全性。结果观察组总有效率97.62%,明显高于对照组的59.52%,两组患者治疗前及治疗后第1天,第7天,神经功能缺损评分对比差异无统计学意义（P〉0.05）,但治疗14d后,差异有统计学意义（P〈0.05）。观察组对全血粘度、血浆粘度、血小板粘附率及纤维蛋白原等血液指标改善方面,明显高于治疗前,且明显高于对照组,差异均有统计学意义（P〈0.05）。且未发生不良反应。结论金纳多治疗急性缺血性脑卒中疗效确切,且无明显不良反应,安全可靠,值得临床推广使用。

Objective To observe and analyze the clinical efficacy and security of Ginaton in the treatment of acute ischemic stroke. Methods 84 cases with acute ischemic stroke in our hospital from January 2012 to December 2013 were selected, they were randomly divided into the observation group and the control group in the order, each group had 42 cases, the observation group was given Ginaton intravenous injection on the basis of conventional treatment, the control group was given Xuesetong intravenous injection on the basis of conventional treatment, the two groups were continuously applied 14 days. The two groups were given examination of neurological function and blood rheology Xuesetong intravenous injection before and after the treatment. Simultaneously Recorded adverse events, comparatively analyze the clinical efficacy and security of the two groups. Results The total efficiency of observation group was 97.62%, it was significantly higher than the control group 59.52%.neurological deficit scores had no significant differences of the two groups before and 1 day, 7 days after treatment（P〉0.05）. But 14 days of treatment, the difference had statistically significant（P〈0.05）. The whole blood viscosity, plasma viscosity, platelet adhesion rate and fibrinogen and other blood parameters of the observation group were significantly higher than before treatment, and significantly higher than the control group, the difference had statistically significant（P〈0.05）. There had no adverse reactions occur. Conclusion It is efficacy of Ginaton in the treatment of acute ischemic stroke, there is no significant adverse reactions, it is safe and reliable, and worthy for clinical.